Hello, this is GCCL!
Ms. Yuhwa Choi, COO of GCCL, has been appointed as a member of the
“Safety Evaluation Subcommittee” of the R&D Expert Committee of the Food and Drug Regulatory Science Innovation Council,
organized by the National Institute of Food and Drug Safety Evaluation under the Ministry of Food and Drug Safety.
The R&D Expert Committee of the Regulatory Science Innovation Council
is an official advisory body that establishes policies and execution frameworks
to ensure the safety and foster innovation in the food and pharmaceutical sectors.
💊 Establishing the basic and implementation plans for regulatory science R&D
📜 Setting policy and budget directions 🥼 Supporting product development and cultivating experts
This official advisory committee is composed of experts from industry, academia, research,
and government, ensuring both professionalism and fairness.
Under the committee, there are three subcommittees: Planning & R&D, Product Support, and Human Resource Development.
In addition, specialized committees are formed for detailed policy execution,
and
Ms. Choi serves on the ‘Safety Evaluation’ committee.
GCCL provides comprehensive sample analysis services throughout the entire new drug development cycle,
operating Central Lab, Bioanalytical Lab, and R&D Lab.
We are honored and proud that GCCL’s expertise has been nationally recognized through this appointment.
Beyond being just an analysis service provider,
GCCL serves as a trusted partner in regulatory policy development and industry-policy integration,
growing together with domestic and global pharmaceutical companies.
We will continue to contribute to Korea's regulatory science development and strengthen the drug development ecosystem,
and strive to become a global-standard partner combining both expertise and public responsibility.
We will always strive to be your most trusted partner in clinical trials.
Want to learn more about GCCL? Click the banners below!
> About GCCL > Newsroom > Company News